Grail Inc Stock Price, News & Analysis

GRAIL (NASDAQ: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025. The company's management will deliver a presentation on Tuesday, June 4 at 11:40 a.m. ET in New York. Investors and interested parties can access both live and replay webcasts of the presentation through GRAIL's investor relations website at investors.grail.com. The webcast recording will remain available for a minimum of 30 days following the event.

GRAIL (NASDAQ: GRAL) reported its Q1 2025 financial results, showing significant growth in its cancer detection business. Total revenue reached $31.8M (19% YoY growth), with U.S. Galleri revenue at $28.7M (22% YoY growth). The company completed over 37,000 Galleri tests in Q1. Despite growth, GRAIL posted a net loss of $106.2M, though this represents a 51% improvement YoY. The company maintains a strong cash position of $677.9M, providing runway into 2028. Notably, GRAIL announced positive top-line results from the NHS-Galleri trial's prevalent screening round, showing higher positive predictive value than the PATHFINDER study, while maintaining consistent cancer signal origin accuracy and specificity. The company plans to submit data for premarket approval in H1 2026. Key partnerships include integration with athenahealth's EHR platform and a new educational initiative with actress Kate Walsh called Generation Possible.

GRAIL (NASDAQ: GRAL) has announced a strategic partnership with athenahealth to integrate its Galleri® multi-cancer early detection (MCED) test into athenaCoordinator Core. The integration will enable over 160,000 U.S. clinicians on athenahealth's network to seamlessly order the Galleri test through their electronic health record (EHR) system.

The Galleri test, which detects cancer through DNA fragments in blood samples, can screen for multiple deadly cancers before symptoms appear and identify the cancer's origin. The test is prescription-only and recommended for adults with elevated cancer risk, particularly those 50 or older, complementing existing cancer screening methods.

This partnership aims to streamline the ordering process, reduce administrative burden, and increase patient access to early cancer detection services.

GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025, after market close.

The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss their financial performance and business progress. Interested parties can access the live webcast through GRAIL's investor relations website at investors.grail.com.

To participate, attendees should:

• Register via https://grail-q1-financial-results-2025.open-exchange.net/
• Connect at least ten minutes before the scheduled start
• Access the investor relations section for live and recorded webcasts

GRAIL (NASDAQ: GRAL) will present new data on its Galleri® multi-cancer early detection (MCED) test at the AACR Annual Meeting in Chicago, April 25-30, 2025. The presentations include real-world evidence from over 100,000 patients, validating the test's capability to detect multiple cancers and accurately predict cancer signal origin.

Key findings include:

• Confirmation of the test's ability to detect cancer signals across various cancer types, particularly those without recommended screening
• Evidence showing reduced cancer risk for one year post-blood draw in patients receiving negative results
• Data supporting annual screening recommendations
• New insights from GRAIL's ctDNA-based targeted methylation platform, demonstrating potential for cancer subtyping through blood samples

GRAIL (NASDAQ: GRAL) has announced the granting of equity awards in the form of restricted stock units (RSUs) to 15 newly hired non-executive employees. The inducement grants, totaling 108,450 shares of GRAIL's common stock, were awarded under the company's Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).

The RSUs feature a four-year vesting schedule, with 25% vesting on February 28, 2026, and subsequent annual vestings on the same date, contingent upon continued employment with GRAIL or its subsidiaries.

GRAIL (Nasdaq: GRAL) has launched Generation Possible, partnering with actress Kate Walsh to raise awareness about multi-cancer early detection (MCED) testing. The initiative highlights the significance of early cancer detection, with Walsh's involvement stemming from her parents' cancer experiences.

Key statistics reveal that 46% of Americans aged 50-75 worry about cancer diagnosis, and approximately 70% of cancer deaths are caused by cancers without recommended screening tests. When detected early, the overall 5-year survival rate is four times higher than late-stage diagnosis.

MCED tests serve as a new screening tool for multiple cancers lacking recommended screening tests today. Available at GenPossible.com, the initiative provides resources including Walsh's personal cancer connection, MCED testing information, and a quiz to determine testing appropriateness. These prescription-only tests are recommended for adults with elevated cancer risk, particularly those 50 or older, as a complement to existing cancer screenings.

GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management will deliver a presentation in Boston on Tuesday, March 4, 2025, at 9:10 a.m. ET.

Interested parties can access both live and replay webcasts through the investor relations section of GRAIL's website at investors.grail.com. The presentation recording will remain available for replay for a minimum of 30 days following the event.

GRAIL (NASDAQ: GRAL) reported strong growth in Q4 and full year 2024, with total revenue increasing 26% to $38.3M in Q4 and 35% to $125.6M for the full year. Galleri® test sales exceeded 137,000 units in 2024, driving U.S. Galleri revenue up 45% year-over-year to $108.6M.

Q4 net loss was $97.1M, including $34.6M in Illumina acquisition-related amortization. Full-year net loss reached $2.0B, primarily due to $1.4B in goodwill and intangible assets impairment. The company ended 2024 with a strong cash position of $767M, extending runway into 2028.

Notable developments include TRICARE Health Insurance adding Galleri as a covered benefit for high-risk patients aged 50+ and a new integration with Quest Diagnostics' ordering system, enabling access through 7,400 patient points nationwide. GRAIL completed study visits for two registrational studies in July and plans to complete its modular PMA submission in H1 2026.